SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 2167672

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 2167672

Geriatric Medicine - Market Insights, Competitive Landscape, and Market Forecast - 2034

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 3750
PDF & Excel (2-3 User License)
USD 4688
PDF & Excel (Site License)
USD 5625
PDF & Excel (Global License)
USD 7500

Add to Cart

Geriatric Medicine Market Summary

Overview:

  • The Geriatric Medicine market is estimated at USD 145 billion in 2025 and is projected to reach USD 250 billion by 2034. Growth is anchored in the rapidly aging global population, the rising burden of chronic and age-related diseases, and the continued introduction of novel therapies for conditions common in older adults.
  • The global Geriatric Medicine market is growing at a CAGR of 6.3% during the forecast period from 2026 to 2034.
  • By indication, the cardiovascular diseases segment dominated the Geriatric Medicine market with a 27% share in 2025.
  • By route of administration, the oral segment dominated the Geriatric Medicine market with a share of 68% in 2025.
  • By distribution channel, the retail pharmacies segment dominated the Geriatric Medicine market with a share of 46% in 2025.
  • By product type, the branded segment dominated the Geriatric Medicine market with a share of 55% in 2025.
  • North America dominated the global Geriatric Medicine market revenue with a share of 38% in 2025, representing the highest regional market share globally.

Geriatric medicine encompasses the pharmaceuticals, vaccines, and therapies used to prevent, treat, and manage the diseases and conditions that commonly affect older adults. The category spans therapies across the major age-related disease areas, including cardiovascular disease, cancer, neurological disorders such as Alzheimer's disease, Parkinson's disease, and dementia, musculoskeletal disorders such as osteoarthritis and osteoporosis, diabetes, respiratory disease, and other conditions, together with vaccines for older adults such as influenza, pneumococcal, shingles, and respiratory syncytial virus vaccines. These medicines are developed and marketed by leading pharmaceutical companies including Pfizer, Novartis, Roche, Johnson & Johnson, Merck, AbbVie, AstraZeneca, Sanofi, Eli Lilly, and Bayer, and by generic and biosimilar manufacturers. Geriatric medicines are delivered through oral, injectable, topical, and other routes, and distributed through hospital, retail, and online pharmacies, in both branded and generic forms. Older adults are the largest consumers of medicines, frequently managing multiple chronic conditions simultaneously, a situation known as multimorbidity and polypharmacy. Over the past decade, the field has advanced with novel therapies for age-related diseases, including disease-modifying treatments for Alzheimer's disease and new vaccines for older adults, while generics and biosimilars have expanded access. Driven by the rapidly aging global population and the rising burden of chronic disease, geriatric medicine is a large and steadily growing area of the pharmaceutical market.

Geriatric Medicine Market Key Growth Drivers

  • The rapidly aging global population is the primary driver, with the World Health Organization projecting the number of people aged 60 and older to reach 2.1 billion by 2050, expanding the population requiring medical care.
  • The rising burden of chronic and age-related diseases, including cardiovascular disease, cancer, dementia, diabetes, and musculoskeletal disorders, is expanding demand for geriatric medicines.
  • The high prevalence of multimorbidity and polypharmacy among older adults, who often manage multiple chronic conditions, increases medication use.
  • The introduction of novel therapies for age-related diseases, including disease-modifying treatments for Alzheimer's disease and new vaccines for older adults, is expanding the treatment landscape.
  • Expanding healthcare access, insurance coverage, and long-term care infrastructure is broadening access to geriatric medicines.
  • The growth of generics and biosimilars is expanding access to affordable medicines for the large elderly population, particularly in emerging markets.
  • The convergence of population aging, rising chronic disease burden, and therapeutic innovation is expected to sustain steady growth in the global Geriatric Medicine market through 2034.

Key Companies in Geriatric Medicine Market

The competitive landscape is led by the following active developers and manufacturers of medicines and vaccines used in geriatric care:

  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • AstraZeneca plc
  • Sanofi S.A.
  • Eli Lilly and Company
  • Bayer AG

Factors Contributing to the Growth of the Geriatric Medicine Market

Market Drivers

Rapidly Aging Global Population

The rapid aging of the global population is the foundational driver of the geriatric medicine market. According to the World Health Organization, the number of people aged 60 and older is rising rapidly and is projected to reach 2.1 billion by 2050, with the number aged 80 and older growing even faster, while by 2030 one in six people worldwide will be aged 60 or older. Older adults are the largest consumers of medicines, requiring treatment for a wide range of chronic and age-related conditions, and the growth of this population directly expands the demand for geriatric medicines. Aging is occurring across both developed and developing countries, and in several countries, including Japan, the elderly already constitute a very large share of the population. As populations continue to age worldwide, the expanding elderly population is expected to be the leading driver of geriatric medicine demand across the forecast period, generating sustained and growing consumption of medicines and vaccines.

Rising Burden of Chronic and Age-Related Diseases

The rising burden of chronic and age-related diseases is a powerful driver of geriatric medicine demand. Older adults carry a high and rising prevalence of cardiovascular disease, cancer, neurological disorders such as Alzheimer's disease and Parkinson's disease, diabetes, musculoskeletal disorders such as osteoarthritis and osteoporosis, and respiratory disease, each of which requires ongoing treatment. Cardiovascular disease and cancer are leading causes of death among older adults, and the prevalence of dementia and other age-related conditions is rising with population aging. The chronic nature of these conditions generates long-term, recurring treatment, and the growing number of older adults with these diseases expands the treated population. As the burden of chronic and age-related disease continues to rise with population aging, this trend is expected to be a significant driver of geriatric medicine demand across the forecast period.

Market Restraints

Despite steady momentum, the Geriatric Medicine market faces material constraints. Polypharmacy in older adults raises significant risks of adverse drug reactions, drug-drug interactions, and medication errors, which can limit prescribing and require careful management. Age-related changes in pharmacokinetics and pharmacodynamics, including altered drug metabolism and excretion, complicate dosing and increase the risk of adverse effects, and frailty and comorbidity add further complexity. Medication adherence is a persistent challenge among older adults, affected by complex regimens, cognitive impairment, and physical limitations, which can reduce effectiveness. Cost and reimbursement pressures constrain access, particularly for high-cost novel therapies, and pricing pressure, including drug price negotiation under measures such as the Inflation Reduction Act that targets medicines heavily used by the elderly, and generic and biosimilar erosion, compress revenue for established products. The historical underrepresentation of older adults in clinical trials limits evidence for this population. Regulatory requirements for drugs and vaccines are rigorous and costly, and development timelines are long. Finally, uneven healthcare access, affordability constraints, and limited geriatric care infrastructure in some regions can restrict access and adoption across parts of the forecast period.

Geriatric Medicine Market Segment Analysis

The Geriatric Medicine Market is segmented by indication (cardiovascular diseases, oncology, neurological disorders, musculoskeletal disorders, diabetes, respiratory diseases, others), route of administration (oral, injectable, topical, others), distribution channel (retail pharmacies, hospital pharmacies, online pharmacies), product type (branded, generic), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Indication

Dominant Subsegment: Cardiovascular Diseases.

The cardiovascular diseases segment accounted for 27% of the Geriatric Medicine market in 2025. Cardiovascular disease dominates because it is the most prevalent and among the deadliest chronic conditions in older adults, and its treatment involves a large and widely used array of medicines, including antihypertensives, lipid-lowering agents such as statins, anticoagulants and antiplatelets, and heart failure therapies. The high prevalence of hypertension, coronary artery disease, atrial fibrillation, and heart failure among the elderly, and the chronic, lifelong nature of their treatment, drive the largest share of geriatric medicine use. Oncology represents a large and high-value indication, driven by the rising cancer burden in older adults and the use of high-cost targeted therapies, immunotherapies, and other agents, and it is a major growth area. Neurological disorders, including Alzheimer's disease, Parkinson's disease, and dementia, represent a large and rapidly growing indication, reinforced by new disease-modifying therapies, and diabetes, musculoskeletal disorders, respiratory disease, and other indications add substantial demand. Nonetheless, the prevalence, chronicity, and broad treatment of cardiovascular disease in older adults secure the leadership of this segment across the forecast period, with oncology and neurology growing strongly.

By Route of Administration

Dominant Subsegment: Oral.

The oral segment accounted for 68% of the Geriatric Medicine market in 2025. Oral administration dominates because the majority of medicines used to manage the chronic conditions common in older adults, including antihypertensives, lipid-lowering agents, oral antidiabetics, analgesics, and many central nervous system and other agents, are taken orally. Oral medicines are convenient, suitable for self-administration and long-term chronic use, and widely available as low-cost generics, making them the mainstay of geriatric pharmacotherapy and driving the largest share of medication use. The injectable segment is large and growing in value, encompassing high-value biologics, oncology therapies, vaccines, and injectable treatments for age-related diseases, including anti-amyloid antibodies for Alzheimer's disease, and it is a key area of innovation. The topical route serves dermatologic, musculoskeletal, and localized conditions, and other routes, including inhaled and transdermal, add further demand, particularly for respiratory and pain management. Nonetheless, the convenience, suitability for chronic use, and broad availability of oral medicines secure the leadership of the oral segment across the forecast period, with injectables growing in value.

Geriatric Medicine Market Region Analysis

North America accounted for 38% of the global Geriatric Medicine market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the largest and highest-priced pharmaceutical market in the world, a large and growing elderly population, high healthcare spending, and rapid adoption of novel therapies. The United States leads on the strength of high per-capita drug spending, a large aging population, comprehensive coverage for older adults through Medicare, rapid adoption of novel therapies including anti-amyloid antibodies and new vaccines for older adults, and the presence of major developers including Pfizer, Merck, AbbVie, and Eli Lilly. Disease burden is substantial, with a large elderly population affected by cardiovascular disease, cancer, dementia, diabetes, and other age-related conditions. The regulatory environment is highly supportive, with the Food and Drug Administration providing established pathways and a track record of approving novel geriatric-relevant therapies and vaccines. Reimbursement supports treatment, though drug price negotiation under the Inflation Reduction Act, which targets high-cost medicines used by Medicare beneficiaries, is beginning to affect selected products. This combination of market size, aging population, and innovation reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Geriatric Medicine market. The region's elevated CAGR is driven by very large and rapidly aging populations, a rising burden of chronic disease, expanding healthcare access, and growing pharmaceutical markets across China, Japan, India, South Korea, and Southeast Asia. Several countries in the region, including Japan and China, have among the largest and fastest-growing elderly populations in the world, dramatically expanding demand for geriatric medicines. Rising incomes, expanding insurance coverage, and growing healthcare investment are improving access to medicines and vaccines for older adults, and domestic pharmaceutical and generic manufacturing is expanding access. Rising prevalence of cardiovascular disease, cancer, diabetes, and dementia, together with growing awareness and diagnosis, further increases demand. Both multinational and regional companies are expanding their presence. Government initiatives to address aging populations further support growth. The combination of large and rapidly aging populations, rising disease burden, expanding access, and growing pharmaceutical capacity positions Asia-Pacific as the highest-growth region over the forecast period.

Regional Commentary

North America

North America accounted for 38% of the global Geriatric Medicine market revenue in 2025. The United States dominates the region on the strength of the largest pharmaceutical market, a large aging population, comprehensive coverage for older adults, and rapid adoption of novel therapies, while Canada contributes through public drug coverage and Mexico expands access within its growing healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom, and has among the oldest populations in the world. Growth is supported by a high burden of age-related disease, established healthcare systems, advanced generic and biosimilar adoption, and the presence of major developers such as Novartis, Roche, Sanofi, Bayer, and AstraZeneca, while the European Medicines Agency provides established regulatory pathways.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large and rapidly aging populations, a rising burden of chronic disease, expanding healthcare access, and growing pharmaceutical markets across China, Japan, India, South Korea, and Southeast Asia. Japan's aged population, China's rapid aging, and India's generic manufacturing are broadening demand and access.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Aging populations, a rising burden of chronic disease, improving healthcare access, and expanding availability of generics are broadening adoption, while generics play an important role in expanding access to medicines for older adults.

Geriatric Medicine Market Competitive Landscape

The Geriatric Medicine market is classified as Fragmented. A broad field of large pharmaceutical companies, vaccine manufacturers, and generic and biosimilar producers competes across the many disease areas relevant to older adults, led by Pfizer, Novartis, Roche, Johnson & Johnson, and Merck, with AbbVie, AstraZeneca, Sanofi, Eli Lilly, and Bayer holding major franchises and numerous generic manufacturers competing on volume and access. The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Fragmented, spanning many large pharmaceutical companies, vaccine makers, and generic and biosimilar manufacturers across multiple disease areas.
  • Leading players: Pfizer, Novartis, Roche, Johnson & Johnson, and Merck anchor the top tier, with AbbVie, AstraZeneca, Sanofi, Eli Lilly, and Bayer holding major franchises.
  • Geographic reach: Leaders operate global commercial and manufacturing networks, with strong positions across North America, Europe, and Asia-Pacific.
  • Product portfolio strength: Top players hold broad portfolios across cardiovascular, oncology, neurology, diabetes, and vaccines relevant to older adults.
  • Pipeline strength: Deep pipelines in oncology, neurology including Alzheimer's disease, cardiometabolic disease, and vaccines for older adults.
  • Strategic partnerships: Extensive collaborations, licensing, and acquisitions across age-related disease areas shape the competitive landscape.
  • M&A activity: Significant consolidation and acquisitions continue, particularly in oncology, neurology, and cardiometabolic disease.
  • Manufacturing capabilities: Large-scale pharmaceutical, biologic, and vaccine manufacturing, and generic production capacity, are key competitive strengths.
  • Innovation focus: Disease-modifying therapies for Alzheimer's disease, novel oncology and cardiometabolic agents, vaccines for older adults, and biosimilars.

Geriatric Medicine Market Recent Developmental Activities

In 2023, the FDA approved lecanemab (Leqembi) from Eisai and Biogen for Alzheimer's disease, followed by donanemab (Kisunla) from Eli Lilly in 2024. Strategic significance: Introduces disease-modifying therapies for a major age-related neurological disease and opens a large new market.

In 2023, the FDA approved the first respiratory syncytial virus vaccines for older adults, Arexvy from GSK and Abrysvo from Pfizer, with expanded eligibility following in 2024. Strategic significance: Creates a large new vaccine market for a significant respiratory threat to older adults.

Geriatric Medicine Market Segmentation

Geriatric Medicine Market by Indication

  • Cardiovascular Diseases
  • Oncology
  • Neurological Disorders
  • Musculoskeletal Disorders
  • Diabetes
  • Respiratory Diseases
  • Others

Geriatric Medicine Market by Route of Administration

  • Oral
  • Injectable
  • Topical
  • Others

Geriatric Medicine Market by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Geriatric Medicine Market by Product Type

  • Branded
  • Generic

Geriatric Medicine Market by Geography

  • North America Geriatric Medicine Market
  • United States Geriatric Medicine Market Size in USD million (2023-2034)
  • Canada Geriatric Medicine Market Size in USD million (2023-2034)
  • Mexico Geriatric Medicine Market Size in USD million (2023-2034)
  • Europe Geriatric Medicine Market
  • Germany Geriatric Medicine Market Size in USD million (2023-2034)
  • United Kingdom Geriatric Medicine Market Size in USD million (2023-2034)
  • France Geriatric Medicine Market Size in USD million (2023-2034)
  • Italy Geriatric Medicine Market Size in USD million (2023-2034)
  • Spain Geriatric Medicine Market Size in USD million (2023-2034)
  • Rest of Europe Geriatric Medicine Market Size in USD million (2023-2034)
  • Asia-Pacific Geriatric Medicine Market
  • China Geriatric Medicine Market Size in USD million (2023-2034)
  • Japan Geriatric Medicine Market Size in USD million (2023-2034)
  • India Geriatric Medicine Market Size in USD million (2023-2034)
  • Australia Geriatric Medicine Market Size in USD million (2023-2034)
  • South Korea Geriatric Medicine Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Geriatric Medicine Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Geriatric Medicine Market
  • Middle East Geriatric Medicine Market Size in USD million (2023-2034)
  • Africa Geriatric Medicine Market Size in USD million (2023-2034)
  • South America Geriatric Medicine Market Size in USD million (2023-2034)

Key Takeaways from the Geriatric Medicine Market Report Study

  • Market size analysis for the current geriatric medicine market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global geriatric medicine market.
  • Various opportunities available for competitors in the geriatric medicine market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current geriatric medicine market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for geriatric medicine market growth in the future?

Target audience that can benefit from this geriatric medicine market report study

  • Geriatric Medicine product providers
  • Research organizations and consulting companies
  • Geriatric Medicine-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in geriatric medicines
  • Various end-users who want to know more about the geriatric medicine market and the latest therapeutic developments in the geriatric medicine market.

Frequently Asked Questions:

Q1. What is the growth rate of the Geriatric Medicine market?

The Geriatric Medicine market is projected to expand at a CAGR of 6.3% during the forecast period of 2026-2034.

Q2. What is the market size of the Geriatric Medicine market?

The Geriatric Medicine market is estimated at USD 145 billion in 2025 and is projected to reach USD 250 billion by 2034.

Q3. Which region dominates the Geriatric Medicine market?

North America dominated the Geriatric Medicine market with a 38% share of global revenue in 2025, supported by the largest pharmaceutical market, a large aging population, comprehensive coverage for older adults, rapid adoption of novel therapies, and the presence of leading developers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Geriatric Medicine market?

The principal drivers are the rapidly aging global population, projected by the World Health Organization to reach 2.1 billion people aged 60 and older by 2050; the rising burden of chronic and age-related diseases; the high prevalence of multimorbidity and polypharmacy; and the introduction of novel therapies for age-related diseases, including disease-modifying Alzheimer's treatments and new vaccines for older adults, reinforced by expanding access and the growth of generics and biosimilars.

Q5. Who are the major players in the Geriatric Medicine market?

The major players include Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., AstraZeneca plc, Sanofi S.A., Eli Lilly and Company, and Bayer AG, among other active developers and generic manufacturers profiled in the Competitive Landscape section. These companies hold broad portfolios across cardiovascular, oncology, neurology, diabetes, and vaccines relevant to older adults.

Product Code: DISR0182

Table of Contents

1. Geriatric Medicine Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Geriatric Medicine Market Executive Summary

  • 2.1 Market at a Glance

3. Geriatric Medicine Market Key Factors Analysis

  • 3.1 Geriatric Medicine Market Drivers
    • 3.1.1 Rapidly Aging Global Population
    • 3.1.2 Rising Burden of Chronic and Age-Related Diseases
    • 3.1.3 High Prevalence of Multimorbidity and Polypharmacy
    • 3.1.4 Introduction of Novel Therapies for Age-Related Diseases
  • 3.2 Geriatric Medicine Market Restraints and Challenges
    • 3.2.1 Polypharmacy and Adverse Drug Reactions
    • 3.2.2 Adherence and Pharmacokinetic Considerations
    • 3.2.3 Pricing, Reimbursement, and Regulatory Barriers
  • 3.3 Geriatric Medicine Market Opportunities
    • 3.3.1 Novel Therapies and Vaccines for Age-Related Disease
    • 3.3.2 Emerging-Market and Generic Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Geriatric Medicine Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Geriatric Medicine Market Assessment

  • 7.1 By Indication
    • 7.1.1 Cardiovascular Diseases
    • 7.1.2 Oncology
    • 7.1.3 Neurological Disorders
    • 7.1.4 Musculoskeletal Disorders
    • 7.1.5 Diabetes
    • 7.1.6 Respiratory Diseases
    • 7.1.7 Others
  • 7.2 By Route of Administration
    • 7.2.1 Oral
    • 7.2.2 Injectable
    • 7.2.3 Topical
    • 7.2.4 Others
  • 7.3 By Distribution Channel
    • 7.3.1 Retail Pharmacies
    • 7.3.2 Hospital Pharmacies
    • 7.3.3 Online Pharmacies
  • 7.4 By Product Type
    • 7.4.1 Branded
    • 7.4.2 Generic
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Geriatric Medicine Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 Germany Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.2.2 United Kingdom Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.2.3 France Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Geriatric Medicine Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.3.3 India Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Geriatric Medicine Market Size in USD million (2023-2034)
    • 7.5.4 Rest of World
      • 7.5.4.1 Middle East Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Geriatric Medicine Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Geriatric Medicine Market Size in USD million (2023-2034)

8. Geriatric Medicine Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Geriatric Medicine Market Startup Funding and Investment Trends

10. Geriatric Medicine Market Company and Product Profiles

  • 10.1 Pfizer Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Novartis AG
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 F. Hoffmann-La Roche Ltd
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Johnson & Johnson
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Merck & Co., Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 AbbVie Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 AstraZeneca plc
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Sanofi S.A.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Eli Lilly and Company
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10.10 Bayer AG
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

Product Code: DISR0182

List of Tables

  • Table 1: Global Geriatric Medicine Market Size in USD million (2023-2034)
  • Table 2: Global Geriatric Medicine Market Size by Indication in USD million (2023-2034)
  • Table 3: Global Geriatric Medicine Market Size by Route of Administration in USD million (2023-2034)
  • Table 4: Global Geriatric Medicine Market Size by Distribution Channel in USD million (2023-2034)
  • Table 5: Global Geriatric Medicine Market Size by Product Type in USD million (2023-2034)
  • Table 6: Geriatric Medicine Market Size in North America in USD million (2023-2034)
  • Table 7: Geriatric Medicine Market Size in the United States in USD million (2023-2034)
  • Table 8: Geriatric Medicine Market Size in Canada in USD million (2023-2034)
  • Table 9: Geriatric Medicine Market Size in Mexico in USD million (2023-2034)
  • Table 10: Geriatric Medicine Market Size in Europe in USD million (2023-2034)
  • Table 11: Geriatric Medicine Market Size in Germany in USD million (2023-2034)
  • Table 12: Geriatric Medicine Market Size in the United Kingdom in USD million (2023-2034)
  • Table 13: Geriatric Medicine Market Size in France in USD million (2023-2034)
  • Table 14: Geriatric Medicine Market Size in Italy in USD million (2023-2034)
  • Table 15: Geriatric Medicine Market Size in Spain in USD million (2023-2034)
  • Table 16: Geriatric Medicine Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 17: Geriatric Medicine Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 18: Geriatric Medicine Market Size in China in USD million (2023-2034)
  • Table 19: Geriatric Medicine Market Size in Japan in USD million (2023-2034)
  • Table 20: Geriatric Medicine Market Size in India in USD million (2023-2034)
  • Table 21: Geriatric Medicine Market Size in Australia in USD million (2023-2034)
  • Table 22: Geriatric Medicine Market Size in South Korea in USD million (2023-2034)
  • Table 23: Geriatric Medicine Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 24: Geriatric Medicine Market Size in the Rest of the World in USD million (2023-2034)
  • Table 25: Geriatric Medicine Market Size in the Middle East in USD million (2023-2034)
  • Table 26: Geriatric Medicine Market Size in Africa in USD million (2023-2034)
  • Table 27: Geriatric Medicine Market Size in South America in USD million (2023-2034)
  • Table 28: Geriatric Medicine Market Competitive Landscape
  • Table 29: Geriatric Medicine Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Geriatric Medicine Market Drivers
  • Figure 2: Geriatric Medicine Market Restraints
  • Figure 3: Geriatric Medicine Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Geriatric Medicine Market (the United States)
  • Figure 6: Regulatory Analysis of the Geriatric Medicine Market (Europe)
  • Figure 7: Regulatory Analysis of the Geriatric Medicine Market (Japan)
  • Figure 8: Regulatory Analysis of the Geriatric Medicine Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Geriatric Medicine Market
  • Figure 10: Competitive Analysis of the Geriatric Medicine Market
  • Figure 11: Global Geriatric Medicine Market Size in USD million (2023-2034)
  • Figure 12: Global Geriatric Medicine Market Size by Indication in USD million (2023-2034)
  • Figure 13: Global Geriatric Medicine Market Size by Route of Administration in USD million (2023-2034)
  • Figure 14: Global Geriatric Medicine Market Size by Distribution Channel in USD million (2023-2034)
  • Figure 15: Global Geriatric Medicine Market Size by Product Type in USD million (2023-2034)
  • Figure 16: Geriatric Medicine Market Size in North America in USD million (2023-2034)
  • Figure 17: Geriatric Medicine Market Size in the United States in USD million (2023-2034)
  • Figure 18: Geriatric Medicine Market Size in Canada in USD million (2023-2034)
  • Figure 19: Geriatric Medicine Market Size in Mexico in USD million (2023-2034)
  • Figure 20: Geriatric Medicine Market Size in Europe in USD million (2023-2034)
  • Figure 21: Geriatric Medicine Market Size in Germany in USD million (2023-2034)
  • Figure 22: Geriatric Medicine Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 23: Geriatric Medicine Market Size in France in USD million (2023-2034)
  • Figure 24: Geriatric Medicine Market Size in Italy in USD million (2023-2034)
  • Figure 25: Geriatric Medicine Market Size in Spain in USD million (2023-2034)
  • Figure 26: Geriatric Medicine Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 27: Geriatric Medicine Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 28: Geriatric Medicine Market Size in China in USD million (2023-2034)
  • Figure 29: Geriatric Medicine Market Size in Japan in USD million (2023-2034)
  • Figure 30: Geriatric Medicine Market Size in India in USD million (2023-2034)
  • Figure 31: Geriatric Medicine Market Size in Australia in USD million (2023-2034)
  • Figure 32: Geriatric Medicine Market Size in South Korea in USD million (2023-2034)
  • Figure 33: Geriatric Medicine Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 34: Geriatric Medicine Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 35: Geriatric Medicine Market Size in the Middle East in USD million (2023-2034)
  • Figure 36: Geriatric Medicine Market Size in Africa in USD million (2023-2034)
  • Figure 37: Geriatric Medicine Market Size in South America in USD million (2023-2034)
  • Figure 38: Geriatric Medicine Market Competitive Landscape
  • Figure 39: Geriatric Medicine Market Startup Funding and Investment Trends
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!